OrsoBio To Advance TLC-6740 After Successful Obesity Combo Trial

 
• By Alaric DeArment
  
OrsoBio announced Phase Ib/IIa topline data for TLC-6740 combined with Eli Lilly's tirzepatide. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Musculoskeletal

More from Therapy Areas